Fate Therapeutics (FATE) Current Assets (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Current Assets came in at $179.5 million in Q1 2026, down 27.67% YoY from $248.2 million in Q1 2025, and down 13.98% on a QoQ basis from $208.7 million in Q4 2025.
Fate Therapeutics (FATE) Current Assets (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Current Assets data on file, last reported at $179.5 million in Q1 2026.
- Quarterly Current Assets fell 27.67% year-over-year to $179.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.5 million (down 27.67% YoY) and the FY2025 annual result came in at $208.7 million, down 28.5% from the prior year.
- Current Assets retreated to $179.5 million in Q1 2026, from $208.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $599.2 million in Q2 2022 to a low of $179.5 million in Q1 2026.
- A 5-year average of $362.7 million and a median of $331.5 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets decreased 9.94% — and 2025, when it sank 37.06%.
- Tracing FATE's Current Assets over 5 years: stood at $502.1 million in 2022, then tumbled by 33.97% to $331.5 million in 2023, then slipped by 11.95% to $291.9 million in 2024, then retreated by 28.5% to $208.7 million in 2025, then retreated by 13.98% to $179.5 million in 2026.
- The last three Current Assets figures came in at $179.5 million (Q1 2026), $208.7 million (Q4 2025), and $221.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 179.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.53 Mn |
| Dec 31, 2025 | 208.70 Mn |
| Sep 30, 2025 | 221.25 Mn |
| Jun 30, 2025 | 230.40 Mn |
| Mar 31, 2025 | 248.22 Mn |
| Dec 31, 2024 | 291.91 Mn |
| Sep 30, 2024 | 310.29 Mn |
| Jun 30, 2024 | 319.39 Mn |
| Mar 31, 2024 | 394.38 Mn |
| Dec 31, 2023 | 331.54 Mn |
| Sep 30, 2023 | 364.17 Mn |
| Jun 30, 2023 | 392.18 Mn |
| Mar 31, 2023 | 437.89 Mn |
| Dec 31, 2022 | 502.07 Mn |
| Sep 30, 2022 | 535.33 Mn |
| Jun 30, 2022 | 599.16 Mn |
| Mar 31, 2022 | 599.08 Mn |
| Dec 31, 2021 | 633.41 Mn |
| Sep 30, 2021 | 693.71 Mn |
| Jun 30, 2021 | 713.27 Mn |